Understanding Presumed ocular histoplasmosis syndrome
POHS can be found during an examination in someone who has no visual complaint. Typical findings include small chorioretinal scars, changes around the optic disc and absence of vitreous inflammation. These are examination features, not proof that a person sees a corresponding set of spots. [1] [3]
The name presumed reflects the clinical association and continuing uncertainty about the exact causal pathway. Histoplasma is an environmental fungus associated with inhaled exposure, but typical POHS is not considered active fungal growth inside the eye. Rare disseminated histoplasmosis involving the eye is a different diagnosis. [1] [3]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Often no noticed change
Scars away from important central tissue can leave everyday vision unaffected. Discovering scars does not mean that an eye is currently losing sight or needs an injection immediately. [1] [3]
Lines become crooked
A new central vascular complication can make text or edges look wavy. A change from the person’s usual view matters even if the other eye compensates during ordinary tasks. [1] [2]
A patch of reduced detail
Central neovascularization, bleeding or a scar can produce blur or a localized missing area. The same subjective patch can have different causes and cannot show whether treatment is needed without examination. [1] [2] [4]
Scars and active vessels are different findings
Original conceptual schematic; not proof of active fungus, a diagnostic retinal photograph or an individual prognosis. [1] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Scar pattern
Characteristic lesions can be found without symptoms or active inflammation.
- Complication
New vessels near a scar may leak or bleed and affect the macula.
- Matched care
Monitoring, vessel treatment and rehabilitation address different needs.
What is happening—and what remains uncertain
After an exposure associated with systemic histoplasmosis, some people develop a characteristic chorioretinal scar pattern. Many do not recall a lung illness. The precise relationship between infection, host response and the ocular syndrome is still studied, so geography and past illness alone do not establish the diagnosis. [1] [2] [3]
Abnormal new vessels can grow near scars beneath the retina. Leakage or bleeding from these vessels can damage central retinal function. Treatment aims to control this neovascular complication, rather than erase every old histo spot or treat presumed active fungus. [1] [3] [4]
What can look similar?
Active infectious retinitis
Disseminated fungal infection and other infectious retinal inflammation differ from typical POHS. Systemic illness, immune suppression or inflammatory eye findings can change the assessment; the absence of routine antifungal treatment for POHS must not be transferred to those infections. [3]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- History and dilated examinationThe specialist considers symptoms, exposure and residence history, general health and the pattern of lesions. Histoplasma exists beyond the classic Ohio and Mississippi River Valley description; location is a clue, not a definitive test. [2] [3]
- OCT and angiographyOCT can reveal fluid and structural effects near the macula. Fluorescein angiography and selected other imaging help investigate active neovascularization when the examination or symptoms raise concern. [1] [2]
- Separate stable scars from activityAsk whether the findings represent an inactive scar, a suspected active vessel complex or another diagnosis. Follow-up and any clinician-provided home monitoring should reflect that distinction rather than a universal injection schedule. [1] [3] [4]
What may help—and what is still being studied
Monitor uncomplicated scars
Many people need observation and advice about new symptoms rather than immediate treatment. The interval should be set by the examination and risk context; do not assume a stable scar requires no future attention. [1] [3]
Treat active neovascularization
Anti-VEGF injections can improve or stabilize vision in active POHS-related neovascular disease. Retreatment is guided by clinical activity. The amount of permanent central damage and the actual response affect useful vision; small studies do not guarantee a normal result. [4] [5] [6]
Understand what the treatment is for
Antifungals are not typically used for ordinary POHS because active fungus is not believed to be present. Selected laser or photodynamic approaches have a role in particular circumstances, but older treatment evidence predates modern injections and does not rank every current option. [2] [3] [4]
What this can mean for daily life
Notice a new reading change
Follow the eye clinic’s monitoring instructions and report a new central change promptly. Note the onset, affected eye and task; do not use a normal-looking home grid as proof that a scar cannot develop a complication. [1] [2]
Make central tasks accessible
Use larger reflowing text, audio and suitable contrast if central vision remains limited. Rehabilitation helps with function even when treatment has controlled leakage but cannot reverse an established scar. [2] [7]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
HANDLE: aflibercept regimens for POHS-related neovascularization
Both groups improved anatomically and visually; the as-needed group received fewer injections with similar reported outcomes. [5]
Limits and applicability: Small study with no untreated or different-drug comparator; not proof of equivalence for all patients, rare-harm safety or an optimal lifelong schedule.
Bevacizumab outcomes in a larger POHS series
Reported improved mean acuity over follow-up in treated neovascular disease. [6]
Limits and applicability: Nonrandom treatment selection, variable follow-up and lack of an untreated concurrent control limit causal and comparative claims. Observed improvement is not a cure of all scars.
AAO clinical review of POHS management
Distinguishes the common asymptomatic scar pattern from the neovascular complication requiring treatment consideration. [4]
Limits and applicability: A narrative clinical review is not a new systematic head-to-head comparison; some foundational laser evidence is from a different treatment era.
Questions researchers still need to answer
- What host and environmental factors explain why only some exposed people develop the characteristic ocular pattern?
- Which regimen best balances recurrence prevention, visual function and visit burden over many years?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
ASRS — POHS
Focused retinal-specialist explanation of scars, symptoms and neovascular treatment.
National Eye Institute — ocular histoplasmosis syndrome
Patient explanation of central symptoms, testing and low-vision support. Read alongside the CDC distinction from active infection.
CDC — histoplasmosis and POHS distinction
Explicitly distinguishes presumed ocular scars from rare active disseminated eye infection and explains why antifungals are not routine POHS care.
Macular Society
Broader central-vision support, counseling and peer connections. No dedicated POHS clinic or international POHS group is claimed.
Connections listed by the organization.
Questions you may still have
Do histo spots always affect sight?
No. Many scars cause no noticed visual change. Their location and any associated abnormal vessel growth matter. [1] [3]
Why am I not receiving an antifungal?
Typical POHS is not considered active fungal infection in the eye. The treatment question often concerns abnormal new vessels; active disseminated fungal infection is a separate situation requiring different care. [3]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- ASRS — Presumed Ocular Histoplasmosis Syndrome (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NEI — Ocular Histoplasmosis Syndrome (2025; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - CDC — Clinical Overview of Histoplasmosis, POHS section (2024; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - AAO — Management of Presumed Ocular Histoplasmosis Syndrome (2020; review).
Indexed clinical review text read; direct client 403. Historical treatment evidence identified as such.
Checked 2026-10-24 · Public page checked - Toussaint et al. — HANDLE study (2018; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Cionni et al. — Outcomes for intravitreal bevacizumab in POHS-related neovascularization (2012; observational).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Macular Society — support pathways (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Vision loss (n.d.; institution).
Official sudden sight-loss/severe pain emergency versus other urgent visual-change guidance checked; local service routes vary internationally.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.